このページの読み込み中にエラーが発生したようです.
当社チームに通知しましたが、問題が続くようでしたらEメールサポートウィジェットを使ってご連絡ください。
| Trend | Peers | Company |
|---|---|---|
| Is return on equity increasing? | No | No |
| Is net profit margin increasing? | Yes | No |
| Is asset turnover increasing? | No | No |
| Is equity multiplier increasing? | Yes | Yes |
| Competitors Used |
|---|
| Amgen Inc. |
| CSL Limited |
| Vanda Pharmaceuticals Inc. |
| Biogen Inc. |
| Regeneron Pharmaceuticals, Inc. |
| Return on Equity Benchmarks | ||||||||
| Comparable Companies | ||||||||
| AMGN | CMXH.F | VNDA | BIIB | REGN | 4AB | |||
| Return On Equity | ||||||||
| Latest Twelve Months | 68% | 15% | -3% | 10% | 16% | 62% | ||
| Fiscal Year - 1 | 136% | 14% | 0% | 8% | 16% | 35% | ||
| Fiscal Year - 2 | 126% | 20% | 1% | 25% | 21% | 72% | ||
| Fiscal Year - 3 | 73% | 32% | 7% | 14% | 54% | 81% | ||
| Fiscal Year - 4 | 76% | 36% | 5% | 33% | 32% | 186% | ||
| Fiscal Year - 5 | 71% | 41% | 34% | 45% | 21% | -94% | ||
| Average | 92% | 26% | 7% | 23% | 27% | 57% | ||
| Median | 75% | 26% | 3% | 20% | 21% | 67% | ||
| Benchmarks | Ticker | |||||||
| Amgen Inc. | NasdaqGS:AMGN | |||||||
| CSL Limited | OTCPK:CMXH.F | |||||||
| Vanda Pharmaceuticals Inc. | NasdaqGM:VNDA | |||||||
| Biogen Inc. | NasdaqGS:BIIB | |||||||
| Regeneron Pharmaceuticals, Inc. | NasdaqGS:REGN | |||||||
| Financial Performance | ||||||||
| Comparable Companies | ||||||||
| (in millions) | AMGN | CMXH.F | VNDA | BIIB | REGN | 4AB | ||
| Latest Fiscal Year | Dec-24 | Jun-24 | Dec-24 | Dec-24 | Dec-24 | Dec-24 | ||
| LTM Period | Dec-24 | Dec-24 | Dec-24 | Dec-24 | Dec-24 | Dec-24 | ||
| Revenues | ||||||||
| Latest Twelve Months | 33,424 | 15,230 | 199 | 9,676 | 14,202 | 56,334 | ||
| Fiscal Year | 33,424 | 14,800 | 199 | 9,676 | 14,202 | 56,334 | ||
| Fiscal Year - 1 | 28,190 | 13,310 | 193 | 9,836 | 13,117 | 54,318 | ||
| Fiscal Year - 2 | 26,323 | 10,562 | 254 | 10,173 | 12,173 | 58,054 | ||
| Fiscal Year - 3 | 25,979 | 10,310 | 269 | 10,982 | 16,072 | 56,197 | ||
| Fiscal Year - 4 | 25,424 | 9,151 | 248 | 13,445 | 8,497 | 45,804 | ||
| Fiscal Year - 5 | 23,362 | 8,539 | 227 | 14,378 | 6,558 | 33,266 | ||
| Net Income | ||||||||
| Latest Twelve Months | 4,090 | 2,748 | (19) | 1,632 | 4,413 | 4,238 | ||
| Fiscal Year | 4,090 | 2,642 | (19) | 1,632 | 4,413 | 4,238 | ||
| Fiscal Year - 1 | 6,717 | 2,194 | 3 | 1,161 | 3,954 | 4,820 | ||
| Fiscal Year - 2 | 6,552 | 2,255 | 6 | 3,047 | 4,338 | 11,782 | ||
| Fiscal Year - 3 | 5,893 | 2,375 | 33 | 1,556 | 8,075 | 11,468 | ||
| Fiscal Year - 4 | 7,264 | 2,103 | 23 | 4,001 | 3,513 | 4,556 | ||
| Fiscal Year - 5 | 7,842 | 1,919 | 116 | 5,889 | 2,116 | 7,842 | ||
| Total Assets | ||||||||
| Latest Fiscal Quarter Prior | 97,154 | 37,304 | 648 | 26,845 | 33,080 | 134,711 | ||
| Latest Fiscal Quarter | 91,839 | 38,447 | 656 | 28,049 | 37,759 | 135,161 | ||
| Fiscal Year | 91,839 | 38,022 | 656 | 28,049 | 37,759 | 135,161 | ||
| Fiscal Year - 1 | 97,154 | 36,234 | 648 | 26,845 | 33,080 | 134,711 | ||
| Fiscal Year - 2 | 65,121 | 28,346 | 634 | 24,554 | 29,215 | 138,805 | ||
| Fiscal Year - 3 | 61,165 | 18,157 | 594 | 23,877 | 25,435 | 146,529 | ||
| Fiscal Year - 4 | 62,948 | 15,616 | 533 | 24,619 | 17,163 | 150,565 | ||
| Fiscal Year - 5 | 59,707 | 12,314 | 484 | 27,234 | 14,805 | 89,115 | ||
| Fiscal Year - 6 | 66,416 | 10,775 | 332 | 25,289 | 11,735 | 59,352 | ||
| Common Equity | ||||||||
| Latest Fiscal Quarter Prior | 6,232 | 17,177 | 545 | 14,799 | 25,973 | 10,360 | ||
| Latest Fiscal Quarter | 5,877 | 18,559 | 539 | 16,716 | 29,354 | 3,325 | ||
| Fiscal Year | 5,877 | 17,363 | 539 | 16,716 | 29,354 | 3,325 | ||
| Fiscal Year - 1 | 6,232 | 15,786 | 545 | 14,799 | 25,973 | 10,360 | ||
| Fiscal Year - 2 | 3,661 | 14,577 | 527 | 13,398 | 22,664 | 17,254 | ||
| Fiscal Year - 3 | 6,700 | 8,381 | 505 | 10,896 | 18,769 | 15,408 | ||
| Fiscal Year - 4 | 9,409 | 6,528 | 453 | 10,700 | 11,025 | 13,076 | ||
| Fiscal Year - 5 | 9,673 | 5,251 | 411 | 13,343 | 11,090 | (8,172) | ||
| Fiscal Year - 6 | 12,500 | 4,080 | 275 | 13,040 | 8,757 | (8,446) | ||